WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced that investors, journalists and the general
public are invited to listen to a live webcast of the Company's analyst
and investor event on September 18, 2015.
The event will focus on ImmunoGen's strong foundation for growth,
including the advancement of its multi-product pipeline, its proprietary
technology that is enabling the development of novel anticancer
therapies and the Company's core competencies that position it for
success.
The video webcast will begin at 8:30 a.m. ET and will be accessible
through the Investors section of the Company's website, www.immunogen.com.
The meeting is expected to last approximately three hours, including a
short break. An archive of the webcast will be available on the
Company's website through October 2, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells. The Company utilizes
its ADC technology with its antibodies to create ImmunoGen product
candidates and also out-licenses limited rights to use its technology to
other companies. Roche's Kadcyla® is the first marketed
product with ImmunoGen's ADC technology. More information about the
Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150917005042/en/
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media